Apimeds Pharmaceuticals US, Inc.
APUS
$2.27
$0.4625.41%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.01M | 364.40K | 275.60K | 300.00K | 427.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.66M | 364.40K | 275.60K | 300.00K | 427.80K |
| Operating Income | -2.66M | -364.40K | -275.60K | -300.00K | -427.80K |
| Income Before Tax | -2.66M | -402.40K | -311.60K | -332.50K | -449.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.66M | -402.40K | -311.60K | -332.50K | -449.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.66M | -402.40K | -311.60K | -332.50K | -449.40K |
| EBIT | -2.66M | -364.40K | -275.60K | -300.00K | -427.80K |
| EBITDA | -2.66M | -- | -- | -- | -- |
| EPS Basic | -0.26 | -0.05 | -0.04 | -0.04 | -0.06 |
| Normalized Basic EPS | -0.16 | -0.03 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | -0.26 | -0.05 | -0.04 | -0.04 | -0.06 |
| Normalized Diluted EPS | -0.16 | -0.03 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 10.37M | 7.90M | 7.90M | 7.90M | 7.90M |
| Average Diluted Shares Outstanding | 10.37M | 7.90M | 7.90M | 7.90M | 7.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |